

BEFORE THE  
MEDICAL BOARD OF CALIFORNIA  
DEPARTMENT OF CONSUMER AFFAIRS  
STATE OF CALIFORNIA

In the Matter of the Accusation  
Against:

David Michael Kolinsky, M.D.

Physician's and Surgeon's  
Certificate No. A 60010

Respondent.

Case No. 800-2020-069085

DECISION


The attached Stipulated Surrender of License and Order is hereby adopted as the Decision and Order of the Medical Board of California, Department of Consumer Affairs, State of California.

This Decision shall become effective at 5:00 p.m. on

DEC 29 2020

IT IS SO ORDERED DEC 22 2020

MEDICAL BOARD OF CALIFORNIA

  
William Prasifka  
Executive Director

1 XAVIER BECERRA  
Attorney General of California  
2 JANE ZACK SIMON  
Supervising Deputy Attorney General  
3 LAWRENCE MERCER  
Deputy Attorney General  
4 State Bar No. 111898  
455 Golden Gate Avenue, Suite 11000  
5 San Francisco, CA 94102-7004  
Telephone: (415) 510-3488  
6 Facsimile: (415) 703-5480  
*Attorneys for Complainant*  
7

8 **BEFORE THE**  
9 **MEDICAL BOARD OF CALIFORNIA**  
10 **DEPARTMENT OF CONSUMER AFFAIRS**  
11 **STATE OF CALIFORNIA**

12 In the Matter of the Accusation Against:

Case No. 800-2020-069085

13 **DAVID MICHAEL KOLINSKY, M.D.**  
2511 Garden Road, Suite C125  
14 Monterey, CA 93924

**STIPULATED SURRENDER OF  
LICENSE AND ORDER**

15 Physician's and Surgeon's Certificate No. A  
60010,

16 Respondent.

17  
18 IT IS HEREBY STIPULATED AND AGREED by and between the parties to the above-  
19 entitled proceedings that the following matters are true:

20 **PARTIES**

21 1. William Prasifka (Complainant) is the Executive Director of the Medical Board of  
22 California (Board). He brought this action solely in his official capacity and is represented in this  
23 matter by Xavier Becerra, Attorney General of the State of California, by Lawrence Mercer,  
24 Deputy Attorney General.

25 2. David Michael Kolinsky, M.D. (Respondent) is represented in this proceeding by his  
26 attorney Marvin Firestone, M.D., J.D., 1700 El Camino Real, Suite 408, San Mateo, CA 94402.

27 3. On or about April 12, 1996, the Board issued Physician's and Surgeon's Certificate  
28 No. A 60010 to David Michael Kolinsky, M.D. (Respondent). Effective September 29, 2017,

1 Respondent's certificate was revoked, the revocation was stayed, and he was placed on a five-  
2 year probation with terms and conditions. The Physician's and Surgeon's Certificate expired on  
3 April 30, 2020, has not been renewed, and Respondent is currently prohibited from engaging in  
4 the practice of medicine.

5 **JURISDICTION**

6 4. Accusation No. 800-2020-069085 was filed before the Board, and is currently  
7 pending against Respondent. The Accusation and all other statutorily required documents were  
8 properly served on Respondent on October 1, 2020. Respondent timely filed his Notice of  
9 Defense contesting the Accusation. A copy of Accusation No. 800-2020-069085 is attached as  
10 Exhibit A and incorporated by reference.

11 **ADVISEMENT AND WAIVERS**

12 5. Respondent has carefully read, fully discussed with counsel, and understands the  
13 charges and allegations in Accusation No. 800-2020-069085. Respondent also has carefully read,  
14 fully discussed with counsel, and understands the effects of this Stipulated Surrender of License  
15 and Order.

16 6. Respondent is fully aware of his legal rights in this matter, including the right to a  
17 hearing on the charges and allegations in the Accusation; the right to confront and cross-examine  
18 the witnesses against him; the right to present evidence and to testify on his own behalf; the right  
19 to the issuance of subpoenas to compel the attendance of witnesses and the production of  
20 documents; the right to reconsideration and court review of an adverse decision; and all other  
21 rights accorded by the California Administrative Procedure Act and other applicable laws.

22 7. Respondent voluntarily, knowingly, and intelligently waives and gives up each and  
23 every right set forth above.

24 **CULPABILITY**

25 8. Respondent understands that the charges and allegations in Accusation No. 800-2020-  
26 069085, if proven at a hearing, constitute cause for imposing discipline upon his Physician's and  
27 Surgeon's Certificate.





1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28


ENDORSEMENT

The foregoing Stipulated Surrender of License and Order is hereby respectfully submitted for consideration by the Medical Board of California of the Department of Consumer Affairs.

DATED: Nov. 3, 2010

Respectfully submitted,

XAVIER BECERRA  
Attorney General of California  
JANE ZACK SIMON  
Supervising Deputy Attorney General



LAWRENCE MERCER  
Deputy Attorney General  
*Attorneys for Complainant*

SF2020400471  
42372060.docx

**Exhibit A**

**Accusation No. 800-2020-069085**

1 XAVIER BECERRA  
Attorney General of California.  
2 JANE ZACK SIMON  
Supervising Deputy Attorney General  
3 LAWRENCE MERCER  
Deputy Attorney General  
4 State Bar No. 111898  
455 Golden Gate Avenue, Suite 11000  
5 San Francisco, CA 94102-7004  
Telephone: (415) 510-3488  
6 Facsimile: (415) 703-5480  
*Attorneys for Complainant*  
7

8 **BEFORE THE**  
9 **MEDICAL BOARD OF CALIFORNIA**  
10 **DEPARTMENT OF CONSUMER AFFAIRS**  
11 **STATE OF CALIFORNIA**

12 In the Matter of the Accusation Against:

Case No. 800-2020-069085

13 **David Michael Kolinsky, M.D.**  
14 **2511 Garden Road, Suite C125**  
**Monterey, CA 93940**

**A C C U S A T I O N**

15 **Physician's and Surgeon's Certificate**  
16 **No. A 60010,**

Respondent.

17  
18  
19 **PARTIES**

20 1. William Prasifka (Complainant) brings this Accusation solely in his official capacity  
21 as the Executive Director of the Medical Board of California, Department of Consumer Affairs  
22 (Board).

23 2. On or about April 12, 1996, the Medical Board issued Physician's and Surgeon's  
24 Certificate Number A 60010 to David Michael Kolinsky, M.D. (Respondent). On September 29,  
25 2017, the Physician's and Surgeon's Certificate was revoked, the order of revocation stayed, and  
26 a five year probation, with terms and conditions, was imposed. The Physician's and Surgeon's  
27 Certificate expired on April 30, 2020, and has not been renewed. On or about March 14, 2020,  
28 Respondent ceased practicing medicine in California, whereupon his probation tolled.



1  
2 **JURISDICTION**

3 3. This Accusation is brought before the Board, under the authority of the following  
4 laws. All section references are to the Business and Professions Code (Code) unless otherwise  
5 indicated.

6 4. Section 2227 of the Code states:

7 (a) A licensee whose matter has been heard by an administrative law judge of  
8 the Medical Quality Hearing Panel as designated in Section 11371 of the Government  
9 Code; or whose default has been entered, and who is found guilty, or who has entered  
into a stipulation for disciplinary action with the board, may, in accordance with the  
provisions of this chapter:

10 (1) Have his or her license revoked upon order of the board.

11 (2) Have his or her right to practice suspended for a period not to exceed one  
12 year upon order of the board.

13 (3) Be placed on probation and be required to pay the costs of probation  
monitoring upon order of the board.

14 (4) Be publicly reprimanded by the board. The public reprimand may include a  
15 requirement that the licensee complete relevant educational courses approved by the  
board.

16 (5) Have any other action taken in relation to discipline as part of an order of  
17 probation, as the board or an administrative law judge may deem proper.

18 (b) Any matter heard pursuant to subdivision (a), except for warning letters,  
19 medical review or advisory conferences, professional competency examinations,  
20 continuing education activities, and cost reimbursement associated therewith that are  
agreed to with the board and successfully completed by the licensee, or other matters  
made confidential or privileged by existing law, is deemed public, and shall be made  
available to the public by the board pursuant to Section 803.1.

21 5. Section 2234 of the Code, states, in pertinent part:

22 The board shall take action against any licensee who is charged with  
23 unprofessional conduct. In addition to other provisions of this article, unprofessional  
conduct includes, but is not limited to, the following:

24 ... (b) Gross negligence.

25 (c) Repeated negligent acts. To be repeated, there must be two or more  
26 negligent acts or omissions. An initial negligent act or omission followed by a  
27 separate and distinct departure from the applicable standard of care shall constitute  
repeated negligent acts.

28 (1) An initial negligent diagnosis followed by an act or omission medically  
appropriate for that negligent diagnosis of the patient shall constitute a single

negligent act.

(2) When the standard of care requires a change in the diagnosis, act, or omission that constitutes the negligent act described in paragraph (1), including, but not limited to, a reevaluation of the diagnosis or a change in treatment, and the licensee's conduct departs from the applicable standard of care, each departure constitutes a separate and distinct breach of the standard of care.

6. Section 2228.1 of the Code provides, in pertinent part, that the Board shall require a licensee who is disciplined based on inappropriate prescribing resulting in harm to patients, to disclose to his or her patients information regarding his or her probation status. The licensee is required to disclose: Probation status, the length of the probation, the probation end date, all practice restrictions placed on the license by the Board, the Board's telephone number, and an explanation of how the patient can find further information on the licensee's probation on the Board's Internet Web site.

#### FACTUAL ALLEGATIONS

7. At all relevant times, Respondent was providing care and treatment for chronic pain patients, with a specialization in fibromyalgia and myofascial pain syndrome, at his offices in Monterey, California. From September 29, 2017 through March, 2020, Respondent was on probation with the Board, with terms that included clinical competence assessment, a practice monitor, and to maintain a record of all controlled substances prescribed.

8. In and before September, 2017, Patient 1<sup>1</sup>, a 57 year old female, was under Respondent's care and treatment for chronic pain. Respondent provided treatment for the patient's condition with trigger point injections, opiates, muscle relaxants and benzodiazepines. After he was placed on probation, Respondent began to taper the patient's pain medications. In 2017-2018, Oxycontin<sup>2</sup>, 40 mg, TID, #90, was eliminated. Norco<sup>3</sup>, 10/325 mg, 8/day, #240, was

<sup>1</sup> Patient names are redacted to protect privacy rights.

<sup>2</sup> Oxycontin (oxycodone hydrochloride) is a potent narcotic used to treat moderate to severe pain. Oxycontin exposes patients and other users to the risks of opioid addiction, abuse and misuse.

<sup>3</sup> Norco is a trade name for hydrocodone bitartrate and acetaminophen, a controlled substance and an opiate medication with the potential for habituation and use.

1 reduced to #150 (5/day), Soma<sup>4</sup>, #120 was reduced from 4/day to 3/day, with clonazepam<sup>5</sup>; 2  
2 mg/day, added to the regimen. Although he tapered her opioid medications, Respondent did not  
3 perform periodic comprehensive reassessments of her chronic pain, but instead maintained her on  
4 a treatment plan of trigger point injections and medications without appropriate consultations or  
5 referrals for physical therapy, psychotherapy and other adjunct treatments for her condition. In  
6 addition to her opioid medications, Respondent maintained the patient on a benzodiazepine and  
7 muscle relaxant, despite the risk of CNS depression and respiratory arrest presented by this  
8 combination of medications. Whether due to inadequate pain control or a substance abuse  
9 disorder, Patient 1 obtained and used street drugs, including heroin and methamphetamine.  
10 Respondent did not perform a complete physical examination, which would have revealed track  
11 marks as evidence of the patient's intravenous drug abuse, nor did he order routine urine  
12 toxicology screens to detect drug abuse. She died of a drug overdose on February 13, 2019,  
13 approximately a month after being discharged from Respondent's care.

14 9. In and before September 2017, Patient 2, a 38 year old female, was under  
15 Respondent's care and treatment for fibromyalgia. Patient 2 could not tolerate trigger point  
16 injections and Respondent's treatment consisted of prescribing opioids and benzodiazepines.  
17 Prior to September 2017, Patient 2 had been on extremely high doses of opioid medications,  
18 exceeding an MME<sup>6</sup> of 400. In and after 2017, Respondent gradually tapered the patient's opioid  
19 medications. In September, 2017, Respondent prescribed oxycodone hydrochloride<sup>7</sup>, 20 mg, Q  
20 4-6 hours, #150, Dilaudid<sup>8</sup>, 8 mg, BID, #60, Adderall<sup>9</sup>, 30 mg, ½ tablet BID, #30, which dosage

21 <sup>4</sup> Soma (carisoprodol) is a muscle relaxant and a controlled substance, which can have  
22 dangerous addictive side effects when taken with opioids.

23 <sup>5</sup> Clonazepam, which is marketed under the trade name Klonopin, is a benzodiazepine  
24 used to treat panic disorder and which can have dangerous additive side effects when taken in  
25 combination with opioids.

26 <sup>6</sup> Morphine Milligram Equivalents (MME) are used to quantify the amount of opioids  
27 across multiple drugs. Clinicians should use caution when prescribing opioids at any dosage,  
28 should carefully reassess evidence of individual benefits and risks when considering increasing  
dosage to  $\geq 50$  morphine milligram equivalents (MME)/day, and should avoid increasing dosage  
to  $\geq 90$  MME/day or carefully justify a decision to titrate dosage to  $\geq 90$  MME/day.

<sup>7</sup> See fn. 2 above.

<sup>8</sup> Hydromorphone hydrochloride, which is marketed under the trade name Dilaudid, is a  
potent opioid agonist and controlled substance.

<sup>9</sup> Adderall (amphetamine salt combination) is a potent stimulant with a high potential for

1 he modified over time, substituting Percocet<sup>10</sup>, 10/325 mg, for oxycodone HCL, and reducing the  
2 patient's MME to approximately 75 MME/day. At the same time that he was prescribing opioids,  
3 Respondent prescribed Valium, a benzodiazepine, 10 mg, TID, thereby increasing the risk of  
4 respiratory arrest. Patient 2 frequently missed appointments for several months at a time;  
5 however, Respondent continued to prescribe dangerous medications to her without an in-person  
6 meeting, examination or comprehensive reevaluation of the patient's condition. Patient 2 reported  
7 little or no relief from her opioid medications. Despite her lack of improvement, Respondent did  
8 not refer her for physical therapy, psychotherapy or other alternative modes of treatment for her  
9 diagnosis of fibromyalgia.

10 10. In and before September 2017, Patient 3, a 34 year old male, was under Respondent's  
11 care and treatment for myofascial pain syndrome. Respondent's treatment plan consisted of  
12 trigger point injections, opioid and benzodiazepine medications. In September 2017, Respondent  
13 was prescribing methadone<sup>11</sup>, 10 mg, 5/day, oxycodone HCL, 20 mg, BID, #60, and clonazepam,  
14 2 mg, TID, #120. Respondent did not refer the patient for a multidisciplinary approach to treat his  
15 diagnosed myofascial pain syndrome, nor did he perform a periodic comprehensive reevaluation  
16 of the patient's condition. Respondent did taper Patient 3's opioid and benzodiazepine  
17 medications to oxycodone HCL, 10 mg, 1.5 tablets/day, #45, and clonazepam, 1 mg, QD, #30;  
18 however, the combination of opioids and benzodiazepines created a risk of CNS depression and  
19 overdose.

20 11. Patient 4, a 65 year old female, was under Respondent's care and treatment for  
21 myofascial pain syndrome of the neck and shoulders from September 20, 2016 through April 9,  
22 2019. Respondent provided treatment for the patient's chronic pain with trigger point injections  
23 and Percocet, 10/325 mg, TID, #90. This treatment plan remained in place for the course of

24 \_\_\_\_\_  
25 misuse and abuse.

26 <sup>10</sup> Percocet (oxycodone/APAP) is a controlled substance and an opioid indicated for  
27 treatment of moderate to severe pain.

28 <sup>11</sup> Methadone hydrochloride is a controlled substance and an opioid indicated for the  
treatment of pain severe enough to require around-the-clock long-term opioid management and  
for which alternative treatments have failed. Methadone exposes users to the risks of opioid  
addiction, misuse and abuse, which can lead to overdose and death.

1 Patient 4's treatment without appropriate consultations or referrals for multidisciplinary  
2 treatments for her myofascial pain syndrome. The trigger point injections utilized by Respondent  
3 contained local anesthetics, i.e., Marcaine<sup>12</sup>, 0.5%, and lidocaine<sup>13</sup>, 1%. The package insert for  
4 Marcaine states:

5 Local anesthetics should be employed only by clinicians who are well versed in  
6 diagnosis and management of dose-related toxicity and other acute emergencies . . .  
7 and then only after insuring the immediate availability of oxygen, other resuscitative  
8 drugs, cardiopulmonary resuscitative equipment, and the personnel resources needed  
9 for proper management of toxic reactions and related emergencies . . .

10 Although Respondent routinely administered trigger point injections with local anesthetics, he did  
11 not have oxygen, other resuscitative drugs or cardiopulmonary resuscitative equipment available  
12 in his office. Respondent was not certified in basic life support or advanced cardiovascular life  
13 support. On April 9, 2019, while administering trigger point injections on Patient 4, Respondent  
14 performed an injection in the vicinity of the cervical spine. After the injections, Patient 4 reported  
15 that she was not feeling well and, later, stated that both her arms were numb. Patient 4  
16 subsequently collapsed in Respondent's office. Arriving fire department paramedics found her  
17 pulseless and apneic. Patient 4 was rushed to a hospital where she was resuscitated after her  
18 cardiac arrest.

### 19 CAUSE FOR DISCIPLINE

#### 20 (Gross Negligence/Repeated Negligent Acts)

21 12. Respondent David Michael Kolinsky, M.D. is subject to disciplinary action under  
22 section 2234 and/or 2234(b) and/or 2234(c) in that he engaged in unprofessional conduct and/or  
23 gross negligence and/or repeated negligent acts, including but not limited to the following:

24 A. Respondent failed to perform periodic complete reassessment of the patient's  
25 condition and reevaluation of the overall treatment plan;

26 \_\_\_\_\_  
27 <sup>12</sup> Marcaine (bupivacaine hydrochloride) is a local anesthetic. It is longer acting than  
lidocaine and can be used for a spinal block.

28 <sup>13</sup> Lidocaine, which is marketed under the trade name Xylocaine, is a local anesthetic or  
numbing medication used for local or regional anesthesia.

1 B. Respondent limited his treatment of fibromyalgia and myofascial pain syndrome to  
2 trigger point injections and opioid medications and failed to refer his patients for appropriate  
3 multidisciplinary treatment of their conditions, including physical therapy and psychotherapy;

4 C. Respondent failed to conduct a complete physical examination or to perform urine  
5 toxicology screens on Patient 1;

6 D. Respondent prescribed potent and potentially dangerous drugs to Patient 2 without  
7 regular face-to-face evaluations;

8 E. Respondent inappropriately prescribed benzodiazepines in combination with opioids;

9 F. Respondent provided trigger point injections without having basic resuscitative  
10 equipment available for airway management, emergency resuscitative drugs or cardiopulmonary  
11 resuscitative equipment available.

12 **DISCIPLINARY CONSIDERATIONS**

13 13. To determine the degree of discipline, if any, to be imposed on Respondent David  
14 Michael Kolinsky, M.D., Complainant alleges that on or about September 29, 2017, in a prior  
15 disciplinary action titled "In the Matter of the Accusation Against David Michael Kolinsky,  
16 M.D." (Case Number 8002016024569), Respondent's license was placed on probation based on  
17 allegations of inappropriate and excessive prescribing of opioids and benzodiazepines. That  
18 decision is now final and is incorporated by reference as if fully set forth herein.

19 **PRAYER**

20 WHEREFORE, Complainant requests that a hearing be held on the matters herein alleged,  
21 and that following the hearing, the Medical Board of California issue a decision:

22 1. Revoking or suspending Physician's and Surgeon's Certificate Number A 60010,  
23 issued to David Michael Kolinsky, M.D.;

24 2. Revoking, suspending or denying approval of David Michael Kolinsky, M.D.'s  
25 authority to supervise physician assistants and advanced practice nurses;

26 3. Ordering David Michael Kolinsky, M.D., if placed on probation, to pay the Board the  
27 costs of probation monitoring; and


28

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

4. Taking such other and further action as deemed necessary and proper.

**OCT 01 2020**

DATED: \_\_\_\_\_

  
\_\_\_\_\_  
WILLIAM PRASIFKA  
Executive Director  
Medical Board of California  
Department of Consumer Affairs  
State of California  
*Complainant*

SF2020400471  
42275946.docx